Clinical trial
HIV Immune and Virological Responses Following the Administration of IL-2 Either…
NCT00196651 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Terminated
Key facts
| NCT number | NCT00196651 |
|---|---|
| Title | HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection |
| Official title | Randomized Study on HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides (LIPO-6T) in Patients Treated Early With HAART During Primary Infection. ANRS 095 PRIMOVAC |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Biological, Drug |
| Interventions | IL-2, LIPO-6T, ALVAC VIH 1433 |
| Enrollment | 60 |
| Start date | Aug 1, 2000 |
| Completion | Feb 1, 2004 |
| First posted | Sep 20, 2005 |
| Last update posted | Sep 20, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: